These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 8537683)

  • 1. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors.
    Montefiori DC; Pantaleo G; Fink LM; Zhou JT; Zhou JY; Bilska M; Miralles GD; Fauci AS
    J Infect Dis; 1996 Jan; 173(1):60-7. PubMed ID: 8537683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Augmented serum neutralizing activity against primary human immunodeficiency virus type 1 (HIV-1) isolates in two groups of HIV-1-infected long-term nonprogressors.
    Zhang YJ; Fracasso C; Fiore JR; Björndal A; Angarano G; Gringeri A; Fenyö EM
    J Infect Dis; 1997 Nov; 176(5):1180-7. PubMed ID: 9359717
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of in vitro anti-human immunodeficiency virus type 1 antibody production in long-term nonprogressors.
    Rusconi S; Berlusconi A; Papagno L; Colombo MC; De Maddalena C; Riva A; Bagnarelli P; Balotta C; Galli M
    Clin Immunol Immunopathol; 1997 Dec; 85(3):320-3. PubMed ID: 9400632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
    Pilgrim AK; Pantaleo G; Cohen OJ; Fink LM; Zhou JY; Zhou JT; Bolognesi DP; Fauci AS; Montefiori DC
    J Infect Dis; 1997 Oct; 176(4):924-32. PubMed ID: 9333150
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors.
    González N; McKee K; Lynch RM; Georgiev IS; Jimenez L; Grau E; Yuste E; Kwong PD; Mascola JR; Alcamí J
    PLoS One; 2018; 13(3):e0193773. PubMed ID: 29558468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Virion-bound ICAM-1 and activated LFA-1: a combination of factors conferring resistance to neutralization by sera from human immunodeficiency virus type 1-infected individuals independently of the disease status and phase.
    Losier M; Fortin JF; Cantin R; Bergeron MG; Tremblay MJ
    Clin Immunol; 2003 Aug; 108(2):111-8. PubMed ID: 12921757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.
    Zhou JY; Montefiori DC
    J Virol; 1997 Mar; 71(3):2512-7. PubMed ID: 9032392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human immunodeficiency virus (HIV)-positive sera obtained shortly after seroconversion neutralize autologous HIV type 1 isolates on primary macrophages but not on lymphocytes.
    Ruppach H; Nara P; Raudonat I; Elanjikal Z; Rübsamen-Waigmann H; Dietrich U
    J Virol; 2000 Jun; 74(12):5403-11. PubMed ID: 10823844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term nonprogressive infection with human immunodeficiency virus type 1 in a hemophilia cohort.
    Greenough TC; Brettler DB; Kirchhoff F; Alexander L; Desrosiers RC; O'Brien SJ; Somasundaran M; Luzuriaga K; Sullivan JL
    J Infect Dis; 1999 Dec; 180(6):1790-802. PubMed ID: 10558933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects.
    Cecilia D; Kleeberger C; Muñoz A; Giorgi JV; Zolla-Pazner S
    J Infect Dis; 1999 Jun; 179(6):1365-74. PubMed ID: 10228056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inefficient enhancement of viral infectivity and CD4 downregulation by human immunodeficiency virus type 1 Nef from Japanese long-term nonprogressors.
    Tobiume M; Takahoko M; Yamada T; Tatsumi M; Iwamoto A; Matsuda M
    J Virol; 2002 Jun; 76(12):5959-65. PubMed ID: 12021328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection.
    Pantaleo G; Menzo S; Vaccarezza M; Graziosi C; Cohen OJ; Demarest JF; Montefiori D; Orenstein JM; Fox C; Schrager LK
    N Engl J Med; 1995 Jan; 332(4):209-16. PubMed ID: 7808486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Homotypic antibody responses to fresh clinical isolates of human immunodeficiency virus.
    Montefiori DC; Zhou IY; Barnes B; Lake D; Hersh EM; Masuho Y; Lefkowitz LB
    Virology; 1991 Jun; 182(2):635-43. PubMed ID: 1708933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between susceptibility of primary HIV-1 isolates to autologous and heterologous neutralizing antibodies. Hospital Evandro Chagas AIDS Clinical Research Group.
    Bongertz V; Costa CI; Santos VG; João Filho EC; Galvão-Castro B; Morgado MG
    AIDS; 1997 Jul; 11(8):969-75. PubMed ID: 9223730
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralization escape in human immunodeficiency virus type 1-infected long-term nonprogressors.
    Bradney AP; Scheer S; Crawford JM; Buchbinder SP; Montefiori DC
    J Infect Dis; 1999 May; 179(5):1264-7. PubMed ID: 10191234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High prevalence of antibodies to the gp120 V3 region principal neutralizing determinant of HIV-1MN in sera from Africa and the Americas.
    Carrow EW; Vujcic LK; Glass WL; Seamon KB; Rastogi SC; Hendry RM; Boulos R; Nzila N; Quinnan GV
    AIDS Res Hum Retroviruses; 1991 Oct; 7(10):831-8. PubMed ID: 1720630
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralization and enhancement of HIV-1 infection by sera from HIV-1 infected individuals who progress to disease at different rates.
    Jolly PE; Weiss HL
    Virology; 2000 Jul; 273(1):52-9. PubMed ID: 10891407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mother-to-child transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies against primary isolates.
    Scarlatti G; Albert J; Rossi P; Hodara V; Biraghi P; Muggiasca L; Fenyö EM
    J Infect Dis; 1993 Jul; 168(1):207-10. PubMed ID: 8515110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals.
    Moog C; Fleury HJ; Pellegrin I; Kirn A; Aubertin AM
    J Virol; 1997 May; 71(5):3734-41. PubMed ID: 9094648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.